DE69607962D1 - Synthetische peptide und diese enthaltende pharmazeutische zusammensetzungen - Google Patents

Synthetische peptide und diese enthaltende pharmazeutische zusammensetzungen

Info

Publication number
DE69607962D1
DE69607962D1 DE69607962T DE69607962T DE69607962D1 DE 69607962 D1 DE69607962 D1 DE 69607962D1 DE 69607962 T DE69607962 T DE 69607962T DE 69607962 T DE69607962 T DE 69607962T DE 69607962 D1 DE69607962 D1 DE 69607962D1
Authority
DE
Germany
Prior art keywords
peptides
amino acid
pharmaceutical compositions
compositions containing
synthetic peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69607962T
Other languages
English (en)
Other versions
DE69607962T2 (de
Inventor
Edna Mozes
Michael Sela
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of DE69607962D1 publication Critical patent/DE69607962D1/de
Application granted granted Critical
Publication of DE69607962T2 publication Critical patent/DE69607962T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
DE69607962T 1995-06-07 1996-06-06 Synthetische peptide und diese enthaltende pharmazeutische zusammensetzungen Expired - Fee Related DE69607962T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/475,577 US6066621A (en) 1989-12-10 1995-06-07 Synthetic peptides for the treatment of myasthenia gravis
PCT/IL1996/000005 WO1996040777A2 (en) 1995-06-07 1996-06-06 Synthetic peptides and pharmaceutical compositions comprising them

Publications (2)

Publication Number Publication Date
DE69607962D1 true DE69607962D1 (de) 2000-05-31
DE69607962T2 DE69607962T2 (de) 2000-12-07

Family

ID=23888200

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69607962T Expired - Fee Related DE69607962T2 (de) 1995-06-07 1996-06-06 Synthetische peptide und diese enthaltende pharmazeutische zusammensetzungen

Country Status (9)

Country Link
US (1) US6066621A (de)
EP (1) EP0832127B1 (de)
JP (1) JP4065322B2 (de)
AT (1) ATE192164T1 (de)
AU (1) AU718436B2 (de)
CA (1) CA2221646A1 (de)
DE (1) DE69607962T2 (de)
IL (1) IL122443A (de)
WO (1) WO1996040777A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6911526B2 (en) * 1996-07-22 2005-06-28 The Trustees Of Columbia University In The City Of New York Compounds that inhibit the interaction between signal-transducing proteins and the GLGF (PDZ/DHR) domain and uses thereof
IL140592A0 (en) 1998-07-23 2002-02-10 Harvard College Synthetic peptides and methods of use for autoimmune disease therapies
RU2002129112A (ru) * 2000-03-31 2004-03-27 Корикса Корпорейшн (Us) Идентификация потенциально иммунодоминантных пептидов альфа-субъединицы ацетилхолинового рецептора
US7273722B2 (en) * 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
IL141647A0 (en) * 2001-02-26 2002-03-10 Yeda Res & Dev Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
EP4352090A2 (de) 2021-06-07 2024-04-17 Toleranzia AB Fusionsprotein zur behandlung von myasthenia gravis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340012C (en) * 1987-08-17 1998-08-25 Trustees Of Leland Stanford Jr. University Peptide determinant associated with immunity
IL92629A0 (en) * 1989-12-10 1990-08-31 Yeda Res & Dev Direct binding of t-cell epitopes to mhc gene products on intact living antigen presenting cells and the use thereof for identifying epitopes causing autoimmune diseases and pharmaceutical compositions for treating such diseases
US5116944A (en) * 1989-12-29 1992-05-26 Neorx Corporation Conjugates having improved characteristics for in vivo administration
ES2139667T3 (es) * 1992-06-18 2000-02-16 Yeda Res & Dev Peptidos sinteticos para el tratamiento de la miastenia gravis.

Also Published As

Publication number Publication date
IL122443A0 (en) 1998-06-15
WO1996040777A2 (en) 1996-12-19
IL122443A (en) 2007-10-31
JPH11507620A (ja) 1999-07-06
EP0832127B1 (de) 2000-04-26
AU5909596A (en) 1996-12-30
EP0832127A2 (de) 1998-04-01
JP4065322B2 (ja) 2008-03-26
AU718436B2 (en) 2000-04-13
US6066621A (en) 2000-05-23
CA2221646A1 (en) 1996-12-19
DE69607962T2 (de) 2000-12-07
WO1996040777A3 (en) 1997-01-23
ATE192164T1 (de) 2000-05-15

Similar Documents

Publication Publication Date Title
IE891542L (en) Peptides having t cell helper activity
TR199800258T1 (xx) Yeni opioid peptidler.
ES2158360T3 (es) Mimeticos de rotacion en sentido inverso y metodos relacionados con ellos.
ATE108662T1 (de) Antimikrobielle peptide, zusammensetzungen, die diese enthalten, und verwendungen daraus.
WO1996003502A3 (en) Muc1 derived proteins for the diagnosis, imaging and therapy of human cancer
ATE242005T1 (de) P277 peptidanaloge, pharmazeutische zusammenstellung davon zur behandlung und diagnose von diabetes
EE03287B1 (et) T-raku antigeeni retseptori V-piirkonna proteiinid, nende valmistamismeetodid, nende saamiseks vajalik ekspressioonivektor ning bakteriaalne rakk, neid sisaldav farmatseutiline kompositsioon, nende kasutamine medikamentide tootmisel ning diagnoosimee
PT1079849E (pt) Utilizacao de proteinas hmg para a preparacao de medicamentos com actividade citotoxica
DE69607962T2 (de) Synthetische peptide und diese enthaltende pharmazeutische zusammensetzungen
FR2718451B1 (fr) Dérivés de peptides boroniques, leur préparation et leur application en thérapeutique.
IL122445A0 (en) Peptide polymers and pharmaceutical compositions comprising them for treatment of myasthenia gravis
BR9707142A (pt) Polinucleotìdeo purificado, dna, vetor, célula hospedeira, linhagem celular de hibridoma, anticorpo monoclonal, processos para produzir exodus, para aumentar a resistência à infecção por vìrus de imonudeficiência humana (hiv), para tratamento de infecção por vìrus de imonodeficiência humana (hiv), para proteção de células progenitoras de medula óssea contra os efeitos citotóxicos e para tratamento de doenças mieloproliferativas, e, uso de produto de proteina de exodus.
DE69630682D1 (de) Synthetische peptide und diese enthaltende arzneimittel zur behandlung des systemischen lupus erythematodes
FI971427A (fi) Peptidit ja niitä sisältävät farmaseuttiset koostumukset
IL120503A0 (en) Peptides for the treatment of systemic lupus erythematosis and pharmaceutical compositions containing them
Ciardelli et al. Activity of synthetic thymosin. alpha. 1 C-terminal peptides in the azathioprine E-rosette inhibition assay
ES2152285T3 (es) Preparacion farmaceutica basada en la proteina celular clara cc10 y su uso como medicamento y en diagnostico.
RU95120588A (ru) Циклогексапептиды, их смеси, способ их получения и применения
DE69434151D1 (de) Therapeutische inhaltsstoffe
FI961505A0 (fi) Uudet veren koaguloitumisjärjestelmässä terapeuttisesti aktiiviset peptidiyhdisteet, menetelmä niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset
Denes et al. The Effect of Thymopoietin 32–34 (TP3) on Suramin-Induced Inhibition on Delayed type Hypersensitivity in Guinea Pigs
NO900255L (no) Peptider med t-cellehjelperaktivitet.
ATE34382T1 (de) Substituierte dipeptide, verfahren zu ihrer herstellung, diese enthaltende pharmazeutische zusammensetzungen und verfahren zur herstellung dieser pharmazeutischen zusammensetzungen.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee